Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

984
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
984
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.3K
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

810
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
810
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

119
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
119
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

9.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.2K
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

2.4K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
2.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A stochastic simulation-based approach to inform the relapsing mouse model study design for non-clinical assessment of tuberculosis.

Antimicrobial agents and chemotherapy·2025
Same author

Unique Interactions of Novel Rufomycin "Click Chemistry" Analogs with <i>Mtb</i> ClpC1 and Implications.

Journal of medicinal chemistry·2025
Same author

Thioquinazolinones as Antituberculosis Agents Targeting Phosphopantetheinyl Transferase.

Journal of medicinal chemistry·2025
Same author

Redirecting raltitrexed from cancer cell thymidylate synthase to <i>Mycobacterium tuberculosis</i> phosphopantetheinyl transferase.

Science advances·2024
Same author

A systematic efficacy analysis of tuberculosis treatment with BPaL-containing regimens using a multiscale modeling approach.

CPT: pharmacometrics & systems pharmacology·2024
Same author

Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis.

Antimicrobial agents and chemotherapy·2024

Related Experiment Video

Updated: Apr 28, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.4K

Tuberculosis drug discovery and emerging targets.

Khisimuzi Mdluli1, Takushi Kaneko, Anna Upton

  • 1Global Alliance for TB Drug Development, New York, New York.

Annals of the New York Academy of Sciences
|June 13, 2014
PubMed
Summary

New strategies are proposed to discover better tuberculosis (TB) drugs. These approaches aim to create more effective TB therapies that target all bacterial populations for shorter treatment durations.

Keywords:
Mycobacterium tuberculosisdrug discoverydrug regimensnonreplicatingtuberculosis drugs

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.1K
Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria
09:57

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Published on: December 14, 2016

12.0K

Related Experiment Videos

Last Updated: Apr 28, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.4K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.1K
Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria
09:57

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Published on: December 14, 2016

12.0K

Area of Science:

  • Microbiology
  • Drug Discovery
  • Infectious Diseases

Background:

  • Current tuberculosis (TB) treatments are lengthy, complex, and associated with adverse effects and drug interactions.
  • The rise of drug-resistant TB strains presents a significant global health challenge.
  • Existing TB therapies struggle to eliminate all Mycobacterium tuberculosis subpopulations, contributing to prolonged treatment.

Purpose of the Study:

  • To propose novel strategies for generating improved drug leads for tuberculosis.
  • To accelerate the development of more effective and shorter TB treatment regimens.
  • To address the challenge of drug resistance and target all bacterial populations.

Main Methods:

  • Reviewing recent advances in TB drug discovery and pathogenesis.
  • Identifying underexploited sources of chemical matter for drug development.
  • Applying lessons from hit generation and validated drug targets.
  • Exploring lead optimization strategies for TB drug candidates.

Main Results:

  • Recent TB drug discovery efforts have yielded numerous compounds with varying potential.
  • Advances in understanding TB pathogenesis offer new therapeutic targets.
  • New strategies can enhance the efficiency of generating TB drug leads.
  • Targeting all Mycobacterium tuberculosis subpopulations is crucial for shorter treatment.

Conclusions:

  • Developing novel TB drug regimens requires innovative approaches to hit and lead generation.
  • Improved strategies can lead to more efficient discovery of effective TB therapeutics.
  • Future TB drug discovery must focus on compounds that shorten treatment duration and overcome resistance.